Biomedicines MDPI

www.mdpi.com

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, biosimilars, and nano-biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics. Biomedicines publishes high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development, and, ultimately, to clinical use. Therefore, laboratory medicine research, translation medicinal research, and comprehensive preclinical studies are all within the scope of the journal. Scope Pathogenesis and mechanisms of diseases Translational medical research Biomaterial in biomedical research Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology Biomarker discovery and early diagnosis research Drug discovery and drug development, biomedicine, and pharmacotherapy Biopharmaceutical biomedicine: biologics, and biosimilars Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bioimaging, gene therapy, vaccine, cell therapy, and tissue engineering.

Read more

Reach decision makers at Biomedicines MDPI

Lusha Magic

Free credit every month!

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, biosimilars, and nano-biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics. Biomedicines publishes high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development, and, ultimately, to clinical use. Therefore, laboratory medicine research, translation medicinal research, and comprehensive preclinical studies are all within the scope of the journal. Scope Pathogenesis and mechanisms of diseases Translational medical research Biomaterial in biomedical research Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology Biomarker discovery and early diagnosis research Drug discovery and drug development, biomedicine, and pharmacotherapy Biopharmaceutical biomedicine: biologics, and biosimilars Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bioimaging, gene therapy, vaccine, cell therapy, and tissue engineering.

Read more
icon

Country

icon

City (Headquarters)

Basel

icon

Employees

11-50

icon

Estimated Revenue

$10,000,000 to $50,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Editor in Chief

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at Biomedicines MDPI

Free credits every month!

My account

Sign up now to uncover all the contact details